title: Correlation between VDR expression and antiproliferative activity of vitamin D3 compounds in combination with cytostatics.
abstract: Calcitriol is a potent antiproliferative agent against various tumour cells in vitro. Its biological activity is mediated by the vitamin D receptors (VDRs). Here, we present the results of a study on vitamin D3 compounds (calcitriol and its analogue PRI-2191) as potential agents in combined antitumour therapy in vitro. Applying antiproliferative SRB and MTT assays, we measured the growth inhibitory effects of vitamin D compounds applied alone or in combination with either cisplatin or doxorubicin. Next, we examined the correlation of this effect with the presence of nVDR (nuclear VDR). The following cancer cell lines were applied: HL-60 (human leukaemia), SW707 (human colon cancer), A549 (human lung cancer), WEHI-3 (mouse leukaemia). The treatment of tumour cells with the combination of vitamin D compounds and cytostatics decreased the inhibitory concentration 50% (IC50) values compared with the effects of cytostatics applied alone. The synergistic effect was positively correlated with nVDR expression.
authors.affiliation: Department of Experimental Oncology, Institute of Immunology and Experimental Therapy, 12 R. Weigla St., 53-114 Wroclaw, Poland.
authors.forename: Marzena
authors.initials: M
authors.lastname: Pelczynska
authors.forename: Joanna
authors.initials: J
authors.lastname: Wietrzyk
authors.forename: Iwona
authors.initials: I
authors.lastname: Jaroszewicz
authors.forename: Dmitry
authors.initials: D
authors.lastname: Nevozhay
authors.forename: Marta
authors.initials: M
authors.lastname: Switalska
authors.forename: Andrzej
authors.initials: A
authors.lastname: Kutner
authors.forename: Maciej
authors.initials: M
authors.lastname: Zabel
authors.forename: Adam
authors.initials: A
authors.lastname: Opolski
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D002117:Calcitriol / Q000008:administration & dosage / Q000494:pharmacology*; D002467:Cell Nucleus / Q000378:metabolism; D049109:Cell Proliferation / Q000187:drug effects; D002945:Cisplatin / Q000008:administration & dosage / Q000494:pharmacology; D003110:Colonic Neoplasms / Q000188:drug therapy / Q000378:metabolism; D004100:Dihydroxycholecalciferols / Q000008:administration & dosage / Q000494:pharmacology*; D004317:Doxorubicin / Q000008:administration & dosage / Q000494:pharmacology; D004354:Drug Screening Assays, Antitumor; D018922:HL-60 Cells; D006801:Humans; D007150:Immunohistochemistry; D007942:Leukemia, Experimental / Q000188:drug therapy / Q000378:metabolism; D008175:Lung Neoplasms / Q000188:drug therapy / Q000378:metabolism; D051379:Mice; D018167:Receptors, Calcitriol / Q000096:biosynthesis* / Q000378:metabolism
chemical_list: D004100:Dihydroxycholecalciferols; D018167:Receptors, Calcitriol; C023850:1 alpha,24-dihydroxyvitamin D3; D004317:Doxorubicin; D002117:Calcitriol; D002945:Cisplatin